LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies
Status:
Not yet recruiting
Trial end date:
2027-07-01
Target enrollment:
Participant gender:
Summary
This is a phase I, interventional, single arm, open label, treatment study designed to
evaluate the safety and efficacy of LV20.19 CAR -T cells with pirtobrutinib bridging and
maintenance in adult patients with B cell malignancies that have failed prior therapies.